Monthly Communication Report

Corporation:	Merck Canada Inc.
Associated registration:	959141-12241-50
Communication date:	2026-04-15
Posted date:	2026-05-14

Designated Public Office Holders who participated in the communication:	Nasser Haidar, Senior Policy Advisor Office of the Min. responsible for Canada-U.S. Trade, Intergovernmental Affairs and One Canadian Economy, Intergovernmental Affairs Secretariat (IGA) Shalene Curtis-Micallef, Deputy Minister Deputy Minister's Office, Health Canada (HC) Mackenzy Metcalfe, Policy Advisor Office of the Minister of Finance, Finance Canada (FIN) Sandenga Yeba, Director of Policy & Deputy Chief of Staff Office of the Minister of Health, Health Canada (HC) Maggie Chi, Member of Parliament House of Commons Jocelyne Voisin, Senior Assistant Deputy Minister Health Policy Branch, Health Canada (HC) Justine Frame, Policy Advisor Minister's Office, Health Canada (HC) Ritu Banerjee, Assistant Deputy Minister Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED) Annahat Kochhar, Policy Advisor Office of the President of the Treasury Board, Treasury Board Of Canada Secretariat (TBS) Elizabeth Wong, Policy Advisor Treasury Board Of Canada Secretariat (TBS) Pamela Aung-Thin, Assistant Deputy Minister Health products & Food Branch, Health Canada (HC)
List of Details Subject matter Detail Intellectual Property, International Development, International Trade Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines. Research and Development Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework. Intellectual Property, Research and Development Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting. Health, Industry Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes. Health, International Trade, Research and Development Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Responsible Officer who filed this communication report:	David D. Jones
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.